Dual Checkpoint Inhibitor-associated Eosinophilic Enteritis

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2019 Nov 16

PMID 31730503

Citations 8

Authors

J Yang

S M Lagana

Y M Saenger

R D Carvajal

Affiliations

Soon will be listed here.

Abstract

Background: Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events.

Case Presentation: We report a case of dual checkpoint inhibitor-associated hypereosinophilia and eosinophilic enteritis in a patient with advanced cutaneous melanoma. Rapid resolution of peripheral eosinophilia and associated symptoms was achieved with steroids alone.

Conclusions: Immune checkpoint inhibition can trigger inflammation in virtually any organ in the body, leading to diverse clinical manifestations. To our knowledge, this is the first case report of eosinophilic enteritis due to ipilimumab plus nivolumab.

Citing Articles

Immune Checkpoint Inhibitor-Associated Celiac Disease: A Retrospective Analysis and Literature Review.

Gupta M, Graham C, Gupta S Diseases. 2024; 12(12.

PMID: 39727645 PMC: 11727056. DOI: 10.3390/diseases12120315.

Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment.

Mima Y, Ohtsuka T, Ebato I, Nakata Y, Tsujita A, Nakazato Y Biomedicines. 2024; 12(8).

PMID: 39200350 PMC: 11352049. DOI: 10.3390/biomedicines12081886.

A Case Report of Post-COVID-19 Eosinophilic Enteritis: An Uncommon Diagnosis in an Adult.

Ravilla J, He P, Patel A Cureus. 2024; 16(7):e65265.

PMID: 39184805 PMC: 11342823. DOI: 10.7759/cureus.65265.

Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review.

Schiepatti A, Premoli A, Maimaris S, Rizzo M, Marples M, Villani L Drugs Context. 2022; 11.

PMID: 36339292 PMC: 9616105. DOI: 10.7573/dic.2022-6-3.

Strongyloides-An uncommon cause of eosinophilia whilst on durvalumab.

Quah G, Blanchard G, Miller N, Wilson P, Nordman I Cancer Rep (Hoboken). 2022; 5(10):e1682.

PMID: 35852050 PMC: 9575490. DOI: 10.1002/cnr2.1682.

References

Rothenberg M . Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol. 2004; 113(1):11-28. DOI: 10.1016/j.jaci.2003.10.047. View

Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N . Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013; 24(6):1697-703. DOI: 10.1093/annonc/mdt027. View

Weide B, Martens A, Hassel J, Berking C, Postow M, Bisschop K . Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin Cancer Res. 2016; 22(22):5487-5496. PMC: 5572569. DOI: 10.1158/1078-0432.CCR-16-0127. View

Simson L, Ellyard J, Dent L, Matthaei K, Rothenberg M, Foster P . Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007; 178(7):4222-9. DOI: 10.4049/jimmunol.178.7.4222. View

Carretero R, Sektioglu I, Garbi N, Salgado O, Beckhove P, Hammerling G . Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015; 16(6):609-17. DOI: 10.1038/ni.3159. View

Zhang M, Li Y . Eosinophilic gastroenteritis: A state-of-the-art review. J Gastroenterol Hepatol. 2016; 32(1):64-72. DOI: 10.1111/jgh.13463. View

Caldwell J, Collins M, Stucke E, Putnam P, Franciosi J, Kushner J . Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol. 2014; 134(5):1114-24. PMC: 4254306. DOI: 10.1016/j.jaci.2014.07.026. View

Rosner S, Kwong E, Shoushtari A, Friedman C, Betof A, Brady M . Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 2018; 7(3):690-697. PMC: 5852343. DOI: 10.1002/cam4.1356. View

Khan S, Orenstein S . Eosinophilic gastroenteritis. Gastroenterol Clin North Am. 2008; 37(2):333-48, v. DOI: 10.1016/j.gtc.2008.02.003. View

10.

van Haelst Pisani C, Kovach J, Kita H, Leiferman K, Gleich G, Silver J . Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood. 1991; 78(6):1538-44. View

11.

Occhipinti M, Falcone R, Onesti C, Marchetti P . Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. Drug Saf Case Rep. 2018; 5(1):12. PMC: 5849760. DOI: 10.1007/s40800-018-0078-z. View

12.

Pineton de Chambrun G, Dufour G, Tassy B, Riviere B, Bouta N, Bismuth M . Diagnosis, Natural History and Treatment of Eosinophilic Enteritis: a Review. Curr Gastroenterol Rep. 2018; 20(8):37. DOI: 10.1007/s11894-018-0645-6. View

13.

Voskens C, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C . The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013; 8(1):e53745. PMC: 3544906. DOI: 10.1371/journal.pone.0053745. View

14.

Tsuyuki S, Tsuyuki J, Einsle K, Kopf M, Coyle A . Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. J Exp Med. 1997; 185(9):1671-9. PMC: 2196297. DOI: 10.1084/jem.185.9.1671. View

15.

Lwin T, Melton S, Genta R . Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. Mod Pathol. 2010; 24(4):556-63. DOI: 10.1038/modpathol.2010.221. View

16.

Bernard-Tessier A, Jeanville P, Champiat S, Lazarovici J, Voisin A, Mateus C . Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur J Cancer. 2017; 81:135-137. DOI: 10.1016/j.ejca.2017.05.017. View

17.

Khan S . Eosinophilic gastroenteritis. Best Pract Res Clin Gastroenterol. 2005; 19(2):177-98. DOI: 10.1016/j.bpg.2005.01.009. View

18.

Sosman J, Bartemes K, Offord K, Kita H, Fisher S, Kefer C . Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res. 1995; 1(8):805-12. View

19.

MacDonald D, Gordon A, Kajitani H, Enokihara H, Barrett A . Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. Br J Haematol. 1990; 76(2):168-73. DOI: 10.1111/j.1365-2141.1990.tb07867.x. View

20.

Mirza S, Hill E, Ludlow S, Nanjappa S . Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res. 2017; 27(3):271-273. DOI: 10.1097/CMR.0000000000000326. View